株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膵外分泌機能不全:パイプライン製品の分析

Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 293887
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.63円で換算しております。
Back to Top
膵外分泌機能不全:パイプライン製品の分析 Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017
出版日: 2017年06月13日 ページ情報: 英文 42 Pages
概要

膵外分泌機能不全(EPI)は膵外分泌酵素の欠乏を特徴とする疾患で、消化不良を引き起こします。下痢、軟便、脂肪分が吸収されない脂肪便、ビタミン欠乏、食欲不振、原因不明の体重減少といった症状があります。治療には、膵酵素補充療法(PERT)、生活習慣の改善などがあります。

当レポートでは、世界における膵外分泌機能不全治療薬のパイプライン製品について取り上げ、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

膵外分泌機能不全の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

膵外分泌機能不全:治療薬開発に従事している企業

  • Anthera Pharmaceuticals Inc
  • Celleron Therapeutics Ltd
  • Cilian AG
  • Laboratoires Mayoly Spindler SAS
  • Nordmark Arzneimittel GmbH & Co KG

薬剤プロファイル

休止中のプロジェクト

中止されたプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9424IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Exocrine Pancreatic Insufficiency - Overview
    • Exocrine Pancreatic Insufficiency - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Exocrine Pancreatic Insufficiency - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development
    • Anthera Pharmaceuticals Inc
    • Celleron Therapeutics Ltd
    • Cilian AG
    • Laboratoires Mayoly Spindler SAS
    • Nordmark Arzneimittel GmbH & Co KG
  • Exocrine Pancreatic Insufficiency - Drug Profiles
    • burlulipase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cilase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CXD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • liprotamase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-1819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Exocrine Pancreatic Insufficiency - Dormant Projects
  • Exocrine Pancreatic Insufficiency - Discontinued Products
  • Exocrine Pancreatic Insufficiency - Product Development Milestones
    • Featured News & Press Releases
      • May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
      • Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
      • Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency
      • Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
      • Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
      • Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
      • Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
      • Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
      • Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
      • Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
      • Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1 2017
  • Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1 2017
  • Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2017
  • Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top